The US Food and Drug Administration (FDA) has released for consultation a new proposed framework on how to regulate health information technology (IT), including mobile medical device applications ("apps") according to risk.
Mobile medical applications can best be understood as programs run on a mobile device such as a smartphone or tablet that allow a user to access a medical technology wherever and whenever they wish. For example, a smartphone application that uses a camera's phone to determine if a skin growth is likely cancerous would be considered a mobile medical application, as would a huge array of other already-cleared applications.
Members of the medical device industry have long been wary of excessive or duplicative federal intervention in the mobile medical application space. Two issues seem to come to the forefront time and again:
Which agencies should regulate medical apps-the US Food and Drug Administration (FDA), the Federal Communications Commission (FCC), the Federal Trade Commission (FTC), or just FDA?
Which aspects of a mobile medical application should be regulated? Are all healthcare applications technically medical devices requiring premarket approval or premarket notification? And what of the mobile device that runs the application?
Those questions were answered in part in 2014, with both FDA and FTC releasing guidance documents regarding various aspects of mobile medical applications. FDA, for its part, said that it plans to exercise "enforcement discretion" regarding mobile medical applications, only going after those that would clearly be a medical device, while leaving all others to FTC.
But legislators have been insistent that government regulators from various agencies work together.
In 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was passed into law, and with it a requirement that FDA, Office of the National Coordinator for Health Information Technology (ONC) and FCC all work together to develop a cohesive approach toward health IT.
Section 618 of FDASIA called for the group to specifically consider mobile medical applications, how to best promote innovation in health IT, patient safety and regulatory simplicity.
The overarching goal of the initiative was to simplify health IT regulations such that companies understand which agency's-FDA or FCC-requirements they will be expected to meet and how they can expect to meet them when they want to bring a new product to market.
FDA, FCC and ONC all said they were looking to consider three things:
Then, in September 2013, ONC's HIT Committee released a set of draft recommendations that were meant to guide the development of the framework to be developed and finalized later by FDA, ONC and FCC.
The extensive report made three general observations:
In addition, the ONC report says that FDA needs to address four "main" issues now facing mobile health technologies:
Further, the report called for FDA to regulate certain devices while avoiding regulation of others:
| Potentially Should be Regulated | Most Likely Shouldn't be Regulated |
|---|---|
EHRs (installed and SaaS) Hospital information systems-of-systems Decision support algorithms Visualization tools for anatomic, tissue images, medical imaging and waveforms Health information exchange software Electronic/robotic patient care assistants Templating software tools for digital image surgical planning | Claims processing software Health benefit eligibility software Practice management / Scheduling / Inventory management software General purpose communication applications (e.g., email, paging) used by health professionals Software using historical claims data to predict future utilization/cost of care Cost effectiveness analytic software Electronic guideline distribution software Disease registries |
On 3 April 2014, FDA, FCC and ONC released their final FDASIA Health IT Report, Proposed Strategy and Recommendations for a Risk-Based Framework.
Immediately, the report says it focused its energies on three categories of health IT:
The first, it notes, poses "limited or no risk to patient safety, and thus do not require additional oversight. The second, such as data capture or clinical decision-making software, represent a "generally low" level of risk compared to the benefits available. Accordingly, the report says health management software-even if it meets the definition of medical device-will not be subject to regulation.
That leaves the third category, medical device health IT functions, such as computer-aided detection software, real-time alarms from bedside monitors and robotic surgery planning tools, all of which are already subject to FDA oversight.
The FDASIA report calls on FDA to "provide greater clarity related to several aspects of medical device regulation involving health IT," including:
But the report concedes that there are ways for FDA to refine its regulation of medical device health IT products under a proposed risk-based framework. That framework, the report says, should be based on four "key priority areas":
These four areas are important in that they can be tailored according to risk, are relevant at all aspects of the product lifecycle, and support innovation and patient safety, the report explains.
Ultimately, the report provides few concrete suggestions, but rather establishes a framework for future work by FDA to be done, and establishes "next steps" for health IT regulation.
However, the report also calls for the creation of a Health IT Safety Center, which would be run by ONC as a public-private entity with input from FDA, FCC and the Agency for Healthcare Research and Quality (AHRQ). The center would be charged with promoting patient safety, as well as "assisting in the creation of a sustainable, integrated health IT learning system that avoids regulatory duplication and leverages and complements existing and ongoing efforts," FDA wrote.
Comments on the report are currently being accepted, although a due date was not provided.
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.
We welcome your feedback. Please let us know how we can continue to improve your experience.